Genmab A/S (OTCMKTS:GNMSF - Get Free Report) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $208.09 and traded as high as $215.30. Genmab A/S shares last traded at $212.55, with a volume of 134 shares changing hands.
Genmab A/S Price Performance
The firm has a market capitalization of $14.04 billion, a price-to-earnings ratio of 12.06 and a beta of 0.91. The stock has a fifty day moving average of $208.09 and a two-hundred day moving average of $205.73.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $3.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.88 by $1.17. The business had revenue of $765.14 million during the quarter, compared to the consensus estimate of $761.09 million. Genmab A/S had a return on equity of 19.23% and a net margin of 35.11%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
